- Therapy-Related Acute Megakaryoblastic Leukemia in a Lung Cancer Patient
-
Moon JJ, Nam MH, Lim CS, Lee CK, Cho Y, Yoon SY
- KMID: 1791911
- Ann Lab Med.
- 2014 Mar;34(2):155-158.
- doi: 10.3343/alm.2014.34.2.155
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Progressive Multiple Cystic Changes in Both Lungs in a Patient Treated with Gefitinib for Lung Adenocarcinoma with Multiple Lung Metastases
-
Ryu YJ, Chun EM, Lee SN, Shim SS
- KMID: 1705587
- Korean J Radiol.
- 2014 Apr;15(2):300-304.
- doi: 10.3348/kjr.2014.15.2.300
Gefitinib is regarded as a relatively safe agent for the treatment of an advanced non-small cell lung cancer (NSCLC). Pulmonary toxicity such as interstitial lung disease associated with gefitinib is... -
- CITED
-
- Close
- SHARE
-
- Close
- A Phase II Study of Vinorelbine, Mitomycin C and Cisplatin Chemotherapy for Advanced Non-Small Cell Lung Cancer
-
Kwon MR, Jeong TY, Yuh YJ, Kim SR
- KMID: 759617
- Korean J Intern Med.
- 2002 Dec;17(4):240-244.
BACKGROUND: This prospective phase II trial was performed to determine the efficacy and toxicity of mitomycin C, vinorelbine and cisplatin combination chemotherapy for patients with previously untreated stage IIIB... -
- CITED
-
- Close
- SHARE
-
- Close
- Combinational Treatment with Retinoic Acid Derivatives in Non-small Cell Lung Carcinoma In Vitro
-
Choi EJ, Whang YM, Kim SJ, Kim HJ, Kim YH
- KMID: 1785789
- J Korean Med Sci.
- 2007 Sep;22(Suppl):S52-S60.
- doi: 10.3346/jkms.2007.22.S.S52
The growth inhibitory effects of four retinoic acid (RA) derivatives, 9-cis RA, 13-cis RA, N-(4-hydroxyphenyl) retinamide (4-HPR), and all-trans retinoic acid (ATRA) were compared. In addition, the effects of various... -
- CITED
-
- Close
- SHARE
-
- Close
- alpha-Tocopheryl succinate potentiates the paclitaxel-induced apoptosis through enforced caspase 8 activation in human H460 lung cancer cells
-
Lim SJ, Choi MK, Kim MJ, Kim JK
- KMID: 1009395
- Exp Mol Med.
- 2009 Oct;41(10):737-745.
- doi: 10.3858/emm.2009.41.10.080
Paclitaxel is one of the chemotheraputic drugs widely used for the treatment of nonsmall cell lung cancer (NSCLC) patients. Here, we tested the ability of alpha-tocopheryl succinate (TOS), another promising... -
- CITED
-
- Close
- SHARE
-
- Close
- Secondary Prophylaxis of Docetaxel Induced Diarrhea with Loperamide: Case Report
-
Lee HY, Lee YH, Kim MJ, Kim HK
- KMID: 1777697
- J Korean Med Sci.
- 2013 Oct;28(10):1549-1551.
- doi: 10.3346/jkms.2013.28.10.1549
Diarrhea is a common adverse event of docetaxel with 20%-40% of incidence and severe diarrhea occurs in 5%-6%. Several treatment guidelines for chemotherapy induced diarrhea (CID) exist, however the prophylaxis... -
- CITED
-
- Close
- SHARE
-
- Close
- Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer
-
Ahn J, Wee WR, Lee JH, Hyon JY
- KMID: 1098641
- Korean J Ophthalmol.
- 2011 Oct;25(5):355-357.
- doi: 10.3341/kjo.2011.25.5.355
We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC... -
- CITED
-
- Close
- SHARE
-
- Close
- Weekly Low-Dose Docetaxel for Salvage Chemotherapy in Pretreated Elderly or Poor Performance Status Patients with Non-small Cell Lung Cancer
-
Lee KW, Lim JH, Kim JH, Lee CT, Lee JS
- KMID: 1107523
- J Korean Med Sci.
- 2008 Dec;23(6):992-998.
- doi: 10.3346/jkms.2008.23.6.992
Although docetaxel monotherapy has shown clinical benefits for previously treated patients with advanced non-small cell lung cancer (NSCLC), the efficacy of salvage docetaxel chemotherapy for elderly patients or patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Influence of Methylenetetrahydrofolate Reductase C677T Polymorphism on the Risk of Lung Cancer and the Clinical Response to Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer: An Updated Meta-Analysis
-
Zhu N, Gong Y, He J, Xia J, Chen X
- KMID: 1798134
- Yonsei Med J.
- 2013 Nov;54(6):1384-1393.
- doi: 10.3349/ymj.2013.54.6.1384
PURPOSE: Methylenetetrahydrofolate reductase (MTHFR) has been implicated in lung cancer risk and response to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). However, the results are controversial. We performed... -
- CITED
-
- Close
- SHARE
-
- Close
- Economic Evaluation of Gemcitabine-cisplatin Chemotherapy for Non Small-Cell Lung Cancer Patient in an Outpatient Setting
-
Min SH, Ko SK, Lim JY
- KMID: 1083662
- J Korean Acad Nurs.
- 2008 Jun;38(3):363-371.
- doi: 10.4040/jkan.2008.38.3.363
PURPOSE: This analysis was conducted to evaluate the cost-effectiveness of gemcitabine-cisplatin chemotherapy for non small-cell lung cancer patients in an outpatient setting compared with the traditional inpatient setting. METHODS: A... -
- CITED
-
- Close
- SHARE
-
- Close
- The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer
-
Cho BC, Kim JH, Soo RA, Yang CH
- KMID: 1779599
- Yonsei Med J.
- 2010 Jan;51(1):1-8.
- doi: 10.3349/ymj.2010.51.1.1
The strategies of incorporating monoclonal antibodies (MoABs) have now proved efficacy in the first-line treatment of advanced non-small cell lung cancer (NSCLC). These include targeting the vascular endothelial growth factor... -
- CITED
-
- Close
- SHARE
-
- Close
- A Less Intensive Combination of Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer Patients who Have Aged 60 Years or More and Has a Poor Performance Status
-
Min YJ, Ahn JJ, Noh YJ, Cha HJ, Suh JH, Jung JP, Park CR, Jeong AK, Park JH, Lee KM
- KMID: 759697
- Korean J Intern Med.
- 2004 Jun;19(2):109-113.
BACKGROUND: The aim of this study was to evaluate the response, survival, and toxicities of a less intensive combination of paclitaxel and carboplatin, which is used in advanced non-small cell... -
- CITED
-
- Close
- SHARE
-
- Close
- Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
-
Ko YH, Lee MA, Hong YS, Lee KS, Park HJ, Yoo IR, Kim YS, Kim YK, Jo KH, Wang YP, Lee KY, Kang JH
- KMID: 1785624
- Korean J Intern Med.
- 2007 Sep;22(3):178-185.
- doi: 10.3904/kjim.2007.22.3.178
BACKGROUND: Second-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is... -
- CITED
-
- Close
- SHARE
-
- Close
- Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells
-
Pei J, Chu T, Shao M, Teng J, Sha H, Gu A, Li R, Qian J, Mao W, Li Y, Han B
- KMID: 2419116
- Yonsei Med J.
- 2017 May;58(3):581-591.
- doi: 10.3349/ymj.2017.58.3.581
PURPOSE: c-Met and its ligand, hepatocyte growth factor (HGF), play a critical role in oncogenesis and metastatic progression. The aim of this study was to identify inhibited enzymogram and to... -
- CITED
-
- Close
- SHARE
-
- Close
- An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib
-
Kwon T, Rho JK, Lee JC, Park YH, Shin HJ, Cho S, Kang YK, Kim BY, Yoon DY, Yu DY
- KMID: 2155657
- Exp Mol Med.
- 2015 May;47(5):e165.
- doi: 10.1038/emm.2015.24
Redox adaptation is an important concept that explains the mechanisms by which cancer cells survive under persistent endogenous oxidative stress and become resistant to certain anticancer agents. To investigate this... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
-
Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS
- KMID: 2381594
- Korean J Intern Med.
- 2015 Nov;30(6):891-898.
- doi: 10.3904/kjim.2015.30.6.891
BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure. METHODS: Forty-five patients with NSCLC who were... -
- CITED
-
- Close
- SHARE
-
- Close
- Molecularly Targeted Therapy Using Bevacizumab for Non-Small Cell Lung Cancer: a Pilot Study for the New CT Response Criteria
-
Lee HY, Lee KS, Hwang HS, Lee JW, Ahn MJ, Park K, Kim TS, Yi CA, Chung MJ
- KMID: 1119224
- Korean J Radiol.
- 2010 Dec;11(6):618-626.
- doi: 10.3348/kjr.2010.11.6.618
OBJECTIVE: We wanted to compare the efficacy of the new CT response evaluation criteria for predicting the tumor progression-free survival (PFS) with that of RECIST 1.1 in non-small cell lung... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
-
Jo J, Kim SH, Kim YJ, Lee J, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Chung JH, Jeon YK, Lee JS
- KMID: 2418782
- Yonsei Med J.
- 2018 Mar;59(2):202-210.
- doi: 10.3349/ymj.2018.59.2.202
PURPOSE: Previous retrospective studies suggest that anaplastic lymphoma kinase (ALK) mutation-positive (ALK+) non-small cell lung cancer (NSCLC) patients are sensitive to pemetrexed. To determine its efficacy, we retrospectively evaluated clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
-
Jeong JH, Cho BC, Shim HS, Kim HR, Lim SM, Kim SK, Chung KY, Islam SM, Song JJ, Kim SY, Kim JH
- KMID: 1777495
- J Korean Med Sci.
- 2013 Jul;28(7):1005-1014.
- doi: 10.3346/jkms.2013.28.7.1005
Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-kappaB). We investigated the association of non-small cell lung... -
- CITED
-
- Close
- SHARE
-
- Close
- Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer
-
Hong J, Kyung SY, Lee SP, Park JW, Jung SH, Lee JI, Park SH, Sym SJ, Park J, Cho EK, Shin DB, Lee JH
- KMID: 1776611
- Korean J Intern Med.
- 2010 Sep;25(3):294-300.
- doi: 10.3904/kjim.2010.25.3.294
BACKGROUND/AIMS: The efficacy and safety of pemetrexed, gefitinib, and erlotinib administration in previously treated patients with non-small cell lung cancer (NSCLC) were compared. METHODS: The study patients met the following... -
- CITED
-
- Close
- SHARE
-
- Close
